Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
COYA Coya Therapeutics	$5.90 +3.3%	$5.97	$4.65 ▼ $10.24	$98.68M	0.49	72,619 shs	12,660 shs
CTNM Contineum Therapeutics	$3.57 -8.7%	$4.96	$3.43 ▼ $22.00	$92.36M	N/A	81,800 shs	106,097 shs
HILS Hillstream BioPharma	$1.35 -8.8%	$1.35	$0.19 ▼ $2.65	$23.76M	3.08	1.39 million shs	8,443 shs
MGNX MacroGenics	$1.51 -4.4%	$1.49	$0.99 ▼ $5.77	$95.27M	2.2	802,840 shs	273,887 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
COYA Coya Therapeutics	+3.33%	-0.51%	-10.06%	-7.96%	-27.25%
CTNM Contineum Therapeutics	-8.70%	+1.71%	-24.68%	-52.96%	-77.49%
HILS Hillstream BioPharma	0.00%	+1.89%	+15.41%	-28.95%	+245.71%
MGNX MacroGenics	-4.43%	-4.43%	-11.70%	-45.29%	-67.87%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
COYA Coya Therapeutics	2.2514 of 5 stars	3.5	5.0	0.0	0.0	2.5	0.0	0.0
CTNM Contineum Therapeutics	2.4028 of 5 stars	3.6	4.0	0.0	0.0	1.7	0.8	0.6
HILS Hillstream BioPharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MGNX MacroGenics	3.6787 of 5 stars	3.2	1.0	0.0	4.4	2.3	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
COYA Coya Therapeutics	3.00	Buy	$17.00	188.14% Upside
CTNM Contineum Therapeutics	3.20	Buy	$22.50	530.25% Upside
HILS Hillstream BioPharma	0.00	N/A	N/A	N/A
MGNX MacroGenics	2.40	Hold	$5.71	278.43% Upside

Current Analyst Ratings Breakdown

Latest HILS, CTNM, MGNX, and COYA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/20/2025	MGNX MacroGenics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$5.00 ➝ $3.00
5/19/2025	CTNM Contineum Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$25.00 ➝ $20.00
5/15/2025	CTNM Contineum Therapeutics	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$31.00 ➝ $31.00
5/14/2025	MGNX MacroGenics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$8.00 ➝ $3.00
5/14/2025	MGNX MacroGenics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$6.00 ➝ $5.00
5/13/2025	COYA Coya Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00 ➝ $14.00
4/28/2025	COYA Coya Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00 ➝ $14.00
4/22/2025	COYA Coya Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00 ➝ $18.00
3/27/2025	COYA Coya Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00 ➝ $18.00
3/25/2025	MGNX MacroGenics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$4.00 ➝ $2.00
3/20/2025	COYA Coya Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00 ➝ $14.00

(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
COYA Coya Therapeutics	$3.69M	26.78	N/A	N/A	$2.47 per share	2.39
CTNM Contineum Therapeutics	$50M	1.85	$0.56 per share	6.35	($3.72) per share	-0.96
HILS Hillstream BioPharma	N/A	N/A	N/A	N/A	$0.48 per share	N/A
MGNX MacroGenics	$152.43M	0.62	N/A	N/A	$2.46 per share	0.61

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
COYA Coya Therapeutics	-$7.99M	-$1.07	N/A	N/A	N/A	N/A	-31.63%	-27.76%	8/11/2025 (Estimated)
CTNM Contineum Therapeutics	$22.72M	-$1.97	N/A	N/A	N/A	N/A	-49.92%	-20.52%	8/12/2025 (Estimated)
HILS Hillstream BioPharma	-$8.47M	-$0.72	N/A	N/A	N/A	N/A	-188.44%	-149.61%	N/A
MGNX MacroGenics	-$9.06M	-$0.89	N/A	N/A	N/A	-69.07%	-89.42%	-38.57%	8/5/2025 (Estimated)

Latest HILS, CTNM, MGNX, and COYA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	CTNM Contineum Therapeutics	-$0.56	-$0.62	-$0.06	-$0.62	$7.50 million	N/A
5/13/2025	Q1 2025	COYA Coya Therapeutics	-$0.44	-$0.44	N/A	-$0.44	$2.63 million	$257.88 million
5/13/2025	Q1 2025	MGNX MacroGenics	-$0.61	-$0.65	-$0.04	-$0.65	$9.59 million	$13.19 million
3/20/2025	Q4 2024	MGNX MacroGenics	-$0.23	-$0.25	-$0.02	-$0.25	$34.17 million	$49.40 million
3/18/2025	Q4 2024	COYA Coya Therapeutics	-$0.32	-$0.18	+$0.14	-$0.18	$0.10 million	$0.20 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
COYA Coya Therapeutics	N/A	N/A	N/A	N/A	N/A
CTNM Contineum Therapeutics	N/A	N/A	N/A	N/A	N/A
HILS Hillstream BioPharma	N/A	N/A	N/A	N/A	N/A
MGNX MacroGenics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
COYA Coya Therapeutics	N/A	15.31	15.31
CTNM Contineum Therapeutics	N/A	37.06	37.06
HILS Hillstream BioPharma	N/A	3.01	3.01
MGNX MacroGenics	N/A	3.75	3.69

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
COYA Coya Therapeutics	39.75%
CTNM Contineum Therapeutics	N/A
HILS Hillstream BioPharma	13.36%
MGNX MacroGenics	96.89%

Insider Ownership

Company	Insider Ownership
COYA Coya Therapeutics	9.80%
CTNM Contineum Therapeutics	11.30%
HILS Hillstream BioPharma	30.24%
MGNX MacroGenics	13.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
COYA Coya Therapeutics	6	16.73 million	14.70 million	Not Optionable
CTNM Contineum Therapeutics	31	25.87 million	N/A	N/A
HILS Hillstream BioPharma	1	17.60 million	12.28 million	Not Optionable
MGNX MacroGenics	430	63.09 million	55.67 million	Optionable

HILS, CTNM, MGNX, and COYA Headlines

Recent News About These Companies

What is B. Riley's Estimate for MacroGenics Q2 Earnings?

May 24 at 1:41 AM | americanbankingnews.com

Zacks Industry Outlook Highlights Insulet, MacroGenics, Cellectar Biosciences and Allurion Technologies

May 23 at 10:39 PM | nasdaq.com

MacroGenics, Inc. (NASDAQ:MGNX) Holdings Lifted by Frazier Life Sciences Management L.P.

May 23 at 7:51 AM | marketbeat.com

B. Riley Cuts MacroGenics (NASDAQ:MGNX) Price Target to $3.00

May 23 at 2:41 AM | americanbankingnews.com

4 Medical Product Stocks to Watch From a Challenging Industry

May 21 at 12:41 PM | zacks.com

MacroGenics, Inc. (NASDAQ:MGNX) Shares Sold by Vestal Point Capital LP

May 21 at 8:23 AM | marketbeat.com

6MGNX : 4 Analysts Assess Macrogenics: What You Need To Know

May 20, 2025 | benzinga.com

Leerink Partnrs Predicts Reduced Earnings for MacroGenics

May 18, 2025 | americanbankingnews.com

Dimensional Fund Advisors LP Has $2.33 Million Position in MacroGenics, Inc. (NASDAQ:MGNX)

May 17, 2025 | marketbeat.com

MacroGenics, Inc.: MacroGenics Provides Update on Corporate Progress and First Quarter 2025 Financial Results

May 16, 2025 | finanznachrichten.de

Earnings Release: Here's Why Analysts Cut Their MacroGenics, Inc. (NASDAQ:MGNX) Price Target To US$4.50

May 16, 2025 | finance.yahoo.com

Brokerages Set MacroGenics, Inc. (NASDAQ:MGNX) Target Price at $7.43

May 15, 2025 | americanbankingnews.com

MacroGenics (MGNX) Reports Q1 Loss, Lags Revenue Estimates

May 13, 2025 | zacks.com

MacroGenics Provides Update on Corporate Progress and First Quarter 2025 Financial Results

May 13, 2025 | globenewswire.com

A Look at Macrogenics's Upcoming Earnings Report

May 12, 2025 | benzinga.com

MacroGenics, Inc. (NASDAQ:MGNX) Receives Average Rating of "Hold" from Analysts

May 12, 2025 | marketbeat.com

Price T Rowe Associates Inc. MD Decreases Holdings in MacroGenics, Inc. (NASDAQ:MGNX)

May 11, 2025 | marketbeat.com

Schonfeld Strategic Advisors LLC Makes New Investment in MacroGenics, Inc. (NASDAQ:MGNX)

May 7, 2025 | marketbeat.com

MacroGenics Announces Date of First Quarter 2025 Financial Results

May 6, 2025 | globenewswire.com

MacroGenics (MGNX) to Release Earnings on Thursday

May 3, 2025 | marketbeat.com

MacroGenics to Participate in Upcoming Investor Conference

May 1, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

HILS, CTNM, MGNX, and COYA Company Descriptions

Coya Therapeutics NASDAQ:COYA

$5.90 +0.19 (+3.33%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$5.98 +0.08 (+1.36%)

As of 05/23/2025 06:23 PM Eastern

Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic, which is in Phase 2 clinical trial for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. The company was incorporated in 2020 and is headquartered in Houston, Texas.

Contineum Therapeutics NASDAQ:CTNM

$3.56 -0.35 (-8.82%)

As of 05/23/2025 04:00 PM Eastern

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.

Hillstream BioPharma NASDAQ:HILS

$1.35 -0.13 (-8.78%)

As of 05/21/2025

Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) and targeted immuno-oncology novel biologics for the treatment drug resistant cancers. The company's product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-3215, an anti-HER2 monoclonal antibody candidate; and HSB-1940, a Quatrabody that is a proprietary IO biologic in development targeting PD-1. The company was incorporated in 2017 and is based in Bridgewater, New Jersey.

MacroGenics NASDAQ:MGNX

$1.51 -0.07 (-4.43%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$1.50 -0.01 (-0.33%)

As of 05/23/2025 07:04 PM Eastern

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time